Anti-Human Lp-PLA2 (12C5)

Anti-Human Lp-PLA2 (12C5)
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
NOV-DA123.1mg 1 mg - -

Fragen Sie uns nach der Lieferzeit

320,00 €
 
Platelet-Activating Factor Acetylhydrolase (PAFAH) is a secreted enzyme which belongs to the AB... mehr
Produktinformationen "Anti-Human Lp-PLA2 (12C5)"
Platelet-Activating Factor Acetylhydrolase (PAFAH) is a secreted enzyme which belongs to the AB hydrolase superfamily and Lipase family and catalyzes the degradation of platelet-activating factor to biologically inactive products. PAFAH is produced by inflammatory cells and hydrolyzes oxidised phospholipids in LDL. PAFAH has been implicated in the development of atherosclerosis and has also been identified as a marker for cardiac disease. PAFAH might have a major physiologic effect in the presence of inflammatory bodily responses. PAFAH alters the action of PAF by hydrolyzing the sn-2 ester bond to yield the biologically inactive lyso-PAF. PAFAH has specificity for substrates with a short residue at the sn-2 position. Protein function: Lipoprotein-associated calcium-independent phospholipase A2 involved in phospholipid catabolism during inflammatory and oxidative stress response (PubMed:7700381, PubMed:8624782, PubMed:2040620, PubMed:16371369, PubMed:17090529, PubMed:10066756). At the lipid- aqueous interface, hydrolyzes the ester bond of fatty acyl group attached at sn-2 position of phospholipids (phospholipase A2 activity) (PubMed:2040620, PubMed:10504265). Specifically targets phospholipids with a short-chain fatty acyl group at sn-2 position (PubMed:2040620). Can hydrolyze phospholipids with long fatty acyl chains, only if they carry oxidized functional groups (PubMed:2040620, PubMed:8624782). Hydrolyzes and inactivates platelet-activating factor (PAF, 1-O-alkyl- 2-acetyl-sn-glycero-3-phosphocholine), a potent proinflammatory signaling lipid that acts through PTAFR on various innate immune cells (PubMed:10504265, PubMed:10066756, PubMed:7592717, PubMed:11590221, PubMed:7700381, PubMed:18434304, PubMed:16371369, PubMed:8675689, PubMed:8624782). Hydrolyzes oxidatively truncated phospholipids carrying an aldehyde group at omega position, preventing their accumulation in low-density lipoprotein (LDL) particles and uncontrolled proinflammatory effects (PubMed:2040620, PubMed:7700381). As part of high-density lipoprotein (HDL) particles, can hydrolyze phospholipids having long-chain fatty acyl hydroperoxides at sn-2 position and protect against potential accumulation of these oxylipins in the vascular wall (PubMed:17090529). Catalyzes the release from membrane phospholipids of F2-isoprostanes, lipid biomarkers of cellular oxidative damage (PubMed:16371369). [The UniProt Consortium]
Schlagworte: Anti-PAFAH, Anti-PLA2G7, Anti-gVIIA-PLA2, Anti-LDL-PLA(2), Anti-PAF 2-acylhydrolase, Anti-PAF acetylhydrolase, Anti-Group-VIIA phospholipase A2, Anti-LDL-associated phospholipase A2, Anti-Platelet-activating factor acetylhydrolase, Human Lp-PLA2 Antibody
Hersteller: Novoprotein
Hersteller-Nr: DA123

Eigenschaften

Antikörper-Typ: Monoclonal
Klon: 12C5
Konjugat: No
Wirt: Mouse
Spezies-Reaktivität: Human Lp-PLA2 Antibody (12C5)
Format: Affinity Purified

Handhabung & Sicherheit

Lagerung: -20°C
Versand: -20°C (International: -20°C)
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier folgen Informationen zur Produktreferenz. mehr
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Anti-Human Lp-PLA2 (12C5)"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen